Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2024/01/061995
CTRI/2024/01/061995
Not yet recruiting
Phase 4

Effectiveness and safety of Selective serotonin Reuptake inhibitor (SSRI) alone vsSSRI with Methylphenidate sustained release in the patients with moderate to severe obsessive compulsive disorder(OCD) - nil

MGM Medical College and Hospital0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
MGM Medical College and Hospital
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patients with OCD disorder who fulfill the diagnostic criteria according to DSM\-5\.
  • •Patient with Total score more than 16 in Yale\-Brown obsessive\-compulsive disorder scale.
  • •Patients aged between 18\-85 years.
  • •Subjects who Provide written informed consent, willing and able to comply with all aspects of the protocol

Exclusion Criteria

  • •Patient with prior allergic reaction on exposure to Methylphenidate
  • •OCD patients with psychiatric illness except depression and anxiety
  • •Substance abuse or Dependence within the past 6 months except nicotine
  • •History of a seizure disorder or other major neurologic disease.
  • •Patients with psychiatric Instability that made participants potentially unsafe in the evaluating psychiatrists judgment.
  • •Patients with pregnancy or breastfeeding
  • •Patients with known chronic medical illness like, Diabetes Mellitus, Hypertension, Cerebro\-vascular Accident, Ischemic Heart Disease, Coronary Artery Disease etc.
  • •Patients not in a condition to give written informed consent E.g.: Delirium, intellectual disability etc.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 1
Impact of selective serotonine re-uptake-inhibitors on acid sphingomyelinase activity in peripheral leucocytes of healthy adult male volunteersF32F33Depressive episodeRecurrent depressive disorder
DRKS00000280niversitätsklinikum Erlangen Psychiatrische und Psychotherapeutische Klinik18
Completed
Phase 4
Effects of selective serotonin re-uptake inhibition on MOrbidity, mOrtality and mood in Depressed Heart Failure patientsHeart failure and co-morbid depressionMental and Behavioural Disorders
ISRCTN33128015German Federal Ministry of Education and Research (Bundesministerium Für Bildung und Forschung [BMBF]) (Germany)414
Active, not recruiting
Not Applicable
Effects of an antidepressant drug on morbidity, mortality and mood in Depressed Heart Failure patients
EUCTR2007-006609-25-DEJulius Maximilians Universität Würzburg
Active, not recruiting
Phase 1
Selective serotonin reuptake inhibition in patients with advanced gastroesophageal cancer receiving immunochemotherapy: a prospective phase II trialgastroesophageal cancerTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2022-001989-36-ATMed. Univ. Wien, Klinik f. Innere Med I, Onkologie35
Not yet recruiting
Not Applicable
Comparison of the Effect of two groups of antidepressants on the body mass index in patients on long term treatment.
CTRI/2014/07/004785Dr Shreya Hegde60